A randomised, double‐blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine

ConclusionsVortioxetine was noninferior and significantly superior to agomelatine in major depressive disorder patients with previous inadequate response to a single course of SSRI/SNRI monotherapy. Vortioxetine was safe and well tolerated. © 2014 The Authors. Human Psychopharmacology: Clinical and Experimental published by John Wiley & Sons, Ltd.

Source: Human Psychopharmacology: Clinical and Experimental - August 3, 2014 Category: Psychiatry Authors: Stuart A. Montgomery, Rebecca Z. Nielsen, Lis H. Poulsen, Lars Häggström Tags: Research Article Source Type: research